Abstract
The accumulation of leukocytes in various organs contributes to the pathogenesis of a number of human autoimmune diseases such as asthma, rheumatoid arthritis, Crohns disease, ulcerative colitis, hepatitis C, and multiple sclerosis. The inflammatory processes leading to tissue damage and disease are mediated in part by the α4 integrins, α4β1 and α4β7, expressed on the leukocyte cell surface. These glycoprotein receptors modulate cell adhesion via interaction with their primary ligands, vascular cell adhesion molecule (VCAM) and mucosal addressin cell adhesion molecule (MAdCAM), expressed in the affected tissue. Upon binding, the combined integrin / CAM interactions at the cell surface result in firm adhesion of the leukocyte to the vessel wall followed by entry into the affected tissue. Elevated cell adhesion molecule (CAM) expression in various organs has been linked with several autoimmune diseases. Monoclonal antibodies specific for α4 integrins or their CAM ligands can moderate inflammation in animal models suggesting such inhibitors may be useful for treating human inflammatory diseases. The α4 integrins have become well validated drug targets for pharmaceutical companies and numerous publications describing α4 integrin antagonists have recently appeared. This article discusses the rationale for targeting α4 integrins for the treatment of autoimmune disorders and reviews some currently known antagonists. The methods used to identify lead molecules and the progress of selected antagonists toward becoming new drugs will is also discussed. (131 references).
Keywords: alpha 4 integrin, alpha 4 beta 1 antagonist, vcam, mad cam
Current Pharmaceutical Design
Title: Alpha 4 Integrin Antagonists
Volume: 8 Issue: 14
Author(s): David Y. Jackson
Affiliation:
Keywords: alpha 4 integrin, alpha 4 beta 1 antagonist, vcam, mad cam
Abstract: The accumulation of leukocytes in various organs contributes to the pathogenesis of a number of human autoimmune diseases such as asthma, rheumatoid arthritis, Crohns disease, ulcerative colitis, hepatitis C, and multiple sclerosis. The inflammatory processes leading to tissue damage and disease are mediated in part by the α4 integrins, α4β1 and α4β7, expressed on the leukocyte cell surface. These glycoprotein receptors modulate cell adhesion via interaction with their primary ligands, vascular cell adhesion molecule (VCAM) and mucosal addressin cell adhesion molecule (MAdCAM), expressed in the affected tissue. Upon binding, the combined integrin / CAM interactions at the cell surface result in firm adhesion of the leukocyte to the vessel wall followed by entry into the affected tissue. Elevated cell adhesion molecule (CAM) expression in various organs has been linked with several autoimmune diseases. Monoclonal antibodies specific for α4 integrins or their CAM ligands can moderate inflammation in animal models suggesting such inhibitors may be useful for treating human inflammatory diseases. The α4 integrins have become well validated drug targets for pharmaceutical companies and numerous publications describing α4 integrin antagonists have recently appeared. This article discusses the rationale for targeting α4 integrins for the treatment of autoimmune disorders and reviews some currently known antagonists. The methods used to identify lead molecules and the progress of selected antagonists toward becoming new drugs will is also discussed. (131 references).
Export Options
About this article
Cite this article as:
Jackson Y. David, Alpha 4 Integrin Antagonists, Current Pharmaceutical Design 2002; 8 (14) . https://dx.doi.org/10.2174/1381612023394737
DOI https://dx.doi.org/10.2174/1381612023394737 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [Hot topic: Adipocytokines in Nonalcoholic Fatty Liver Disease: Key Players Regulating Steatosis, Inflammation and Fibrosis (Executive Editor: Herbert Tilg)]
Current Pharmaceutical Design Th1/Th17 Cytokine Profile is Induced by Macrophage Migration Inhibitory Factor in Peripheral Blood Mononuclear Cells from Rheumatoid Arthritis Patients
Current Molecular Medicine Perinatal Exposure to Bisphenol A and Developmental Programming of the Cardiovascular Changes in the Offspring
Current Medicinal Chemistry The Role of Chemokines, Cytokines and Adhesion Molecules in Stem Cell Trafficking and Homing
Current Pharmaceutical Design Ex-ante Evaluation of Biotechnology Innovations: the Case of Folate Biofortified Rice in China
Current Pharmaceutical Biotechnology Crystallization and Preliminary Diffraction Studies of Porcine Pancreatic Elastase in Complex with a Novel Inhibitor
Protein & Peptide Letters Clinical Evidence of Herb-Drug Interactions: A Systematic Review by the Natural Standard Research Collaboration
Current Drug Metabolism Current and Emerging Therapeutic Approaches in HCV-Related Mixed Cryoglobulinemia
Current Medicinal Chemistry Prospects for Caspase Inhibitors
Mini-Reviews in Medicinal Chemistry Rapid Analysis of Pharmacology for Infectious Diseases
Current Topics in Medicinal Chemistry New Organ-Specific Pharmacological Strategies Interfering With Signaling Pathways In Inflammatory Disorders/Autoimmune Disorders
Current Signal Transduction Therapy Absorption, Disposition and Pharmacokinetics of Nanoemulsions
Current Drug Metabolism Heme Oxygenase-1 as a Target for the Design of Gene and Pharmaceutical Therapies for Autoimmune Diseases
Current Gene Therapy Beta-Adrenergic Antagonists: Indications and Potential Immunomodulatory Side Effects in the Critically Ill
Current Medicinal Chemistry Heme Oxygenase-1 and Carbon Monoxide: Emerging Therapeutic Targets in Inflammation and Allergy
Recent Patents on Inflammation & Allergy Drug Discovery Cytochrome P450-Mediated Estrogen Metabolites and Autoimmunity: Relationship and Link to Free Radicals
Current Drug Metabolism Proteomics and Mass Spectrometry: What Have We Learned About The Heart?
Current Cardiology Reviews Lymphatics and Inflammation
Current Medicinal Chemistry Engineering Nanomedicines to Overcome Multidrug Resistance in Cancer Therapy
Current Medicinal Chemistry Cytokines and Chemokines as Regulators of Angiogenesis in Health and Disease
Current Pharmaceutical Design